🧬DeCurious.bio/acc
2.2K posts
@YDecurious
Curious about DESCI and a beleiver in the scientific singularity. Degen on the Desci side via @pumpdotscience. Bullish on $BIO and Bio-protocol.
💊 Pfizer invested directly into VitaDAO years ago, essentially a test layer for $BIO 🚨 Fast forward to today: Liquidity is rotating back into the system → post government shutdown recovery starting now → banks regaining lending capacity →AI on deck to borrow more capital for growth 📄 Federal signals are clear inside FOMC Minutes: AI sectors are first in line for capital expansion 🔥 Now layer this: • Clarity Act → compliance filter • Morgan Stanley MSCI regulation → quality control • Capital rotation → real products 👉 The result: BIO Protocol sits directly at the intersection of all 3 🧠 What this means: We’re no longer in a “crypto for crypto market" We’re entering a sector driven market where: AI 🧠 RWA 📊 DeSci 🧬 …Will have individual bull runs ⚡ Reality check: The broad altcoin market can lag for years But niche sectors? 👉 They move FIRST 👉 They move FAST 👉 They absorb early liquidity 🚀 Right now: BIO is on deck as a flagship mover With a non digital product that is supported by blockchain technically. #Crypto #Altcoins #DeSci #AI #RWA #BIOCrypto $VITADao
MINX dissolution data is in. Standard oral minoxidil: basically dumps immediately. MINX 5mg lipid matrix: slow, gradual release for hours -- especially at intestinal pH. We’re going live on @Pumpfun to walk through the data. This is where hair loss drug development gets fun.
MINX dissolution data is in. Standard oral minoxidil: basically dumps immediately. MINX 5mg lipid matrix: slow, gradual release for hours -- especially at intestinal pH. We’re going live on @Pumpfun to walk through the data. This is where hair loss drug development gets fun.
🧵 Over 24 hours, our scientific team and AI scientist infrastructure developed a novel peptide agonist to potentially treat ADHD. Below is our paper for a pre-IND computational feasibility assessment for OX2R-004: an 18-residue peptide agonist designed as a selective OX2R agonist for ADHD. Why this matters? No approved orexin agonists exist anywhere. All marketed orexin drugs are dual OX1R/OX2R antagonists for insomnia. Clinical-stage ones are small molecules for narcolepsy only. We did this with @peptai_ a novel full 8-gate computational pipeline in one shot developed by @BioProtocol community 👇
